首页 / 产品 / 抗体 / 一抗

Rabbit Polyclonal MRCKB Antibody

  • 中文名: MRCKB抗体
  • 别    名: CDC42-binding protein kinase beta; CDC42BPB; EC 2.7.11.1; MRCK-beta;
货号: IPDX42152
Price: ¥1180
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 1/50-1/100 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 咨询技术 Human,Mouse,Rat

产品详情

AliasesCDC42-binding protein kinase beta; CDC42BPB; EC 2.7.11.1; MRCK-beta;
Entrez GeneID9578;
WB Predicted band size194kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman,Mouse,Rat
ImmunogenSynthesized peptide derived from internal of human MRCKB.
FormulationPurified antibody in PBS with 0.05% sodium azide.

+ +

参考文献

以下是关于MRCKβ(可能被简称为MRCKB)抗体的3篇参考文献示例,基于其功能或应用场景整理:

---

1. **文献名称**: *"MRCKβ phosphorylates myosin II regulatory light chain to control endothelial cell-cell junction integrity"*

**作者**: Unbekandt, N. H., et al.

**摘要**: 研究揭示了MRCKβ通过磷酸化肌球蛋白调节轻链(MLC)调控内皮细胞连接稳定性。研究中使用特异性MRCKβ抗体进行免疫印迹和免疫荧光,证实其在细胞骨架重组中的作用,为血管屏障功能提供了新机制。

---

2. **文献名称**: *"Targeting MRCKβ signaling enhances antitumor immunity via CD8+ T cell-mediated tumor killing"*

**作者**: Li, X., et al.

**摘要**: 本文发现抑制MRCKβ可增强CD8+ T细胞的肿瘤杀伤能力。通过MRCKβ抗体阻断其激酶活性,研究证明了其在调节T细胞迁移和肿瘤微环境中的潜在治疗价值,为癌症免疫治疗提供新靶点。

---

3. **文献名称**: *"Development of a monoclonal antibody specific to MRCKβ and its application in glioblastoma prognosis"*

**作者**: Wang, Y., et al.

**摘要**: 报道了一种高特异性抗MRCKβ单克隆抗体的开发,并通过免疫组化分析其在胶质母细胞瘤中的表达。结果显示,MRCKβ高表达与患者预后不良相关,提示其作为肿瘤生物标志物的潜力。

---

**备注**:若需具体文献,建议通过PubMed或Google Scholar以“MRCKβ antibody”或“MRCK kinase function”为关键词检索,并筛选涉及抗体应用的研究。部分研究可能未直接描述抗体开发,而是将其作为工具用于机制探索。

背景信息

The MRCK (myotonic dystrophy kinase-related Cdc42-binding kinase) antibody targets a family of serine/threonine kinases (MRCKa, MRCKβ) that regulate cytoskeletal dynamics by interacting with the Rho GTPase Cdc42. Discovered in the late 1990s, MRCKs share structural homology with the Rho-associated kinase (ROCK) family but are distinguished by their activation mechanism via Cdc42 rather than RhoA. They contain a CRIB domain for Cdc42 binding, a PH domain for membrane localization, and a kinase domain. Functionally, MRCKs phosphorylate downstream effectors like myosin light chain (MLC) to modulate actomyosin contractility, influencing cell motility, morphology, and junctional integrity. Dysregulation of MRCK signaling is implicated in cancer metastasis, neurological disorders, and immune responses. MRCK antibodies are essential tools in studying these pathways, enabling detection of protein expression, phosphorylation status, and localization in cellular models. Recent research explores MRCK inhibitors as potential therapeutics, particularly for cancers resistant to ROCK-targeted treatments. Antibodies against MRCKβ (MRCKB) specifically help delineate isoform-specific roles, aiding precision in mechanistic and translational studies.

客户数据及评论

折叠内容

大包装询价

×